이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Korea’s Celltrion wins drug patent lawsuit case vs J&J in the U.S

Collected: 2016.08.19

Distributed: 2016.08.22

Source: Go Direct

South Korea’s biopharmaceutical company Celltrion Inc. won the court battle over patent right against the U.S-based Johnson & Johnson (J&J), removing a major stumbling block in the Korean drug maker’s plan to market its copycat drug of J&J’s arthritis treatment drug Remicade in the U.S within the year.

A U.S federal judge on Wednesday (local time in the U.S) invalidated the key patent of J&J’s blockbuster arthritis and autoimmune drug Remicade, giving legal go-ahead to Celltrion to market Remsima, biosimilar or low-cost replication, of J&J’s steady seller Remicade.

According to foreign news outlets, U.S. District Judge Mark Wolf in Boston said the patent of the antibodies that J&J’s Janssen Biotech claims to expire in 2018 was already included in an earlier patent. The U.S Patent and Trademark Office in February 2015 reached a similar decision by disapproving the patent application for J&J’s antibodies.

J&J said it will appeal, which means Celltrion may have to wait longer for the final definitive ruling.

The Korean biopharmaceutical company has hoped to sell biosimilar Remsima through Pfizer from October 3 after it gained approval from the U.S. Food and Drug Administration in April this year.

By Lee Dong-in

Read in Korean

List

Previous: Shinhan Bank, Credit CEOs likely candidates for new Shinhan Group chairman

Next: Mirae Asset to offer fund backed by State Farm Bldgs in Dallas